#+OPTIONS: org-inline-image-overlays:t org-image-actual-width:nil
#+ATTR_HTML: :width 40px
* antibacterial targets :l:
** Cell Wall Biosynthesis
*** Beta-lactam antibiotics
**** Why do β-lactam antibiotics inhibit penicillin-binding proteins (transpeptidase)?
(D-Ala)₂ looks a lot like penicillin, so PBP-Serine-OH reacts with penicillin instead of (D-Ala)₂ on the growing peptidoglycan polymer. β-lactam antibiotics irreversibly inhibit PBP.
**** β-lactamase hydrolysis of penicillin
β-lactamase-Ser-OH opens β-lactam ring at carbonyl
**** resistance
***** causes
production of β-lactamase by bacteria
***** mechanism
β-lactamase hydrolyzes the β-lactam ring
**** SAR
***** overcoming resistance
- add bulky functional groups to the acyclic amide to sterically inhibit β-lactamases
- electron withdrawing group to acyclic amide
***** acid stability
- electron withdrawing group as substituent to acyclic amide
- adding acid stability allows the drug to have good oral bioavailability
***** both acid stability and β-lactamase resistance
sterically bulky /and/ electron withdrawing group substituted on the acyclic amide
**** classes :l:
***** Penicillins
****** types by structure :l:
******* methicillin
******* isoxazole
******* ureidopenicillin
******* acidic penicillin
******* amino penicillin
****** Penicillin G/V
******* Pen G IV
******** common use
CNS manifestations of syphillis
******** syphillis—causative agent
Treponema pallidum
******* Pen G IM PCNs
******** common use
major Strep infections
******* Pen V PO
- strep throat
- some dental infections
****** semi-synthetic penicillins :l:
******* Naficillin
******** indication
nosocomial MSSA
******* Methicillin
******* Oxacillin
stable toward acid and β-lactamase
Bactocil
******** brand
******* Dicloxacillin
stable toward acid and β-lactamase
******** brand
- Dycill
- Pathocil
******* Amoxicillin/Ampicillin
******** coverage
- Strep. pneumo. and Intermediate S. pneumo in higher dosage
******** Ampicillin
- DOC for listeria
****** Acidic penicillins :l:
******* Ticarcillin
******** coverage
- Pseudomonas
- Gram-
****** “isoxazole penicillins”
- oxacillin
- dicloxacillin
****** Ureidopenicillins
******* Piperacillin
******** spectrum
- Pseudomonas aeruginosa
- Enterococcus
****** Aminopenicillins
******* ampicillin
******** indication
drug of choice for /Listeria/ infections
******* amoxicillin
******** prodrug
form with unionized amino groups, which would be ionized at physiological pH
****** MSSA
sensitive staph aureus (MSSA); this is /not MRSA/
******* practical uses
bactericidal against staph
****** questions
******* PO only?
- Penicillin V
******* IV only?
- Timentin
- Zosyn
****** physiochemical properties
******* acid-base attacks
acid-catalyzed ring opening of the strained Penam nucleus
******* pH environment
- Stable between 6-7.2
- Do not place in highly acidic or basic environment
****** combinations :l:
******* Amoxicillin + Clavulanic acid
******* Ticarcillin + Clavulanic Acid
******* Ampicillin + Sulbactam
******* Piperacillin + Tazobactam
***** Cephalosporins
****** general structure
[[./cephalosporin_general_structure.png]]
****** avoid with TPN or divalent metal ions
Ceftrioxone (Rocephin)
****** SAR
******* free carboxylic acid at C2
- must be present for antibacterial activity
- prodrugs formed by making an ester with the carboxylic acid at C2
******* 
****** 1st generation
******* Cefazolin
******** brand
Ancef
******** ROA
IV
******** indication
prophylaxis of Staphylococcus infection, esp. in surgery
******** spectrum
Gram-(+)
******* Cephalexin
******** brand
Keflex
******** ROA
PO
******** spectrum
- Gram-(+)
- modest activity against Gram-(-)
******* Cefadroxil
******** ROA
PO
******* Cephalothin
******** ROA
IV
****** 2nd generation
******* Cephamycins
******** common structural feature
7-methoxy group off the 3-cefem nucleus
******** spectrum
- certain anaerobic bacteria
- Bacteroides fragilis
******** drugs :l:
********* cefoxitin
********* cefotetan
********* cefmetazole
******* NON-cephamycins
******** indications
- COPD/bronchitis
- H. influenzae
******** drugs :l:
********* cefaclor
********** brand
Raniclor
********** ROA
PO
********* cefprozil
********** brand
Cefzil
********** ROA
PO
********* cefonicid
********* cefuroxime
********* cefoxitin
****** 3rd generation
******* common structural feature
2-amine-1,3-thiazole ring
******* ROA
parenteral
******* drugs
******** IV :l:
********* Ceftriaxone 
********** brand
Rocephin
********** DOC for
Neisseria meningitis
********** usage
don’t administer within 24h of calcium products e.g. TPN
********* Cefotaxime
********** brand
Claforan
********* Ceftazidime
********** brand
- Fortaz
- Tazicef
********** coverage
- potent inducer of β-lactamase, especially in Enterobacter
- Pseudomonas
- Gram-(-) rods
******** “super hero gen”
********* ceftazidime/avibactam
********* ceftolozane/tazobactam
******** PO :l:
********* Cefixime
********* Cefdinir
********* Cefditore
********* Cefixime
********* Ceftibute
********* Cefoperazone
********* Ceftizoxime
********** brand
Cefizox
****** 4th generation
******* drugs
******** Cefepime
********* ROA
Cefepime
********* brand
Maxipime
****** 5th generation
******* drugs :l:
******** Ceftaroline
********* brand
- Teflaro
- Fosamil
********* ROA
IV
********* spectrum
- MRSA
- S. pneumoniae
- K. pneumoniae
- E. coli
***** Carbapenems
****** cilastin
inhibits renal dehydropeptidase-1, which hydrolyzes the β-lactam ring of imipenem
******* Primaxin
Imipenem + Cilastin
****** drugs :l:
******* Imipenem
******* Meropenem
******* Doripenem
******* Ertapenem
******** brand
Invanz
****** indications
- Basically covers everything (including anaerobes, atypicals, nasty GNRs, PA, etc).
- Ertapenem (Invanz) barely covers anything
****** non-indications
- MRSA
***** Carbacephems
***** Monobactams
****** drugs :l:
******* Aztreonam
******** ROA
IV
******** coverage
- Gram-
**** allergy
***** structures that cause reactivity
- β-lactam ring structure
- S on the β-lactam ring
- R1 group side chains
**** structures
***** [[./isoxazole_ring.png]]
isoxazole ring
***** [[./ampicillin.png]]
ampicillin
***** [[./cephalosporin_core_structure.png]]
cephalosporin
***** nuclei of each class
****** [[./cefem_nucleus.png]]
cefem nucleus
****** [[./penam_nucleus.png]]
penam nucleus
****** [[./monobactam_nucleus.png]]
monobactam nucleus
*** Glycopeptide
**** Vancomycin
*** Glycolipopeptide
**** Telavancin
**** Oritavancin
**** Dalbavancin
*** Miscellaneous
**** Cycloserine
***** side effects
CNS disturbances
***** MOA
- inhibits 2 key enzymes
  - D-alanine racemase
  - D-alanine synthase/ligase
- blocks peptidoglycan cross linking of the myobacterial cell wall
***** indication
TB infections
***** SAR
rigid analog of D-alanine
**** Isoniazid
***** indication
TB infections
**** Ethionamide
**** Ethambutol
**** Teicoplanin
*** Lipopeptides :l:
**** Daptomycin
***** MOA
- lipophillic decanoyl side chain inserts into bacterial cell membrane
- bactericidal
***** indications
**** Polymixins
***** MOA
- detergent-like effect
- loss of cell membrane integrity
- bactericidal
***** indications
- IV agent used to kill nasty infections
- Gram(-) bacteria
**** Bacitracin
***** spectrum
Gram(+)
***** formulation
- topical
- only available in combinations
  - with Polymyxin B (Polysporin™)
  - with Polymyxin B and Neomycin (Neosporin®)
**** Colistin
** Cytoplasmic Membrane 
** DNA Biosynthesis
*** fluroquinolones
**** MOA
- inhibits topoisomerase II (DNA gyrase), which replicates, transcribes, and repairs bacterial DNA
- inhibits topoisomerase IV, which partitions DNA during cell division
- bactericidal
- concentration-dependent
**** structure
[[./fluroroquinolone_keto_enol_structure.png]]
**** SAR
****** CNS side effects
caused by a basic ring system substituent on C-7—pyrrolidine, piperazine, substituted piperazine, bicyclic ring system
****** C-3
must have a carboxylic acid at C-3
****** N-1
1,4-dihydroquinolone portion is essential because it freezes the drug in the correct keto-enol tautometer
****** chelation
- carboxylic acid at C-3
- keto at C-4
chelates divalent and trivalent cations; decreases oral bioavailability
****** fluorine subsitutent
******* at C-6
- good activity against Gram(-) bacteria
- broad spectrum activity
******* at C-6 and C-8
- improves drug absorption and half-life
- increases drug-induced photosensitivity
**** drugs :l:
***** levofloxacin
****** brand
Levaquin
****** spectrum
- Gram(-)
- atypicals
- S. pneumoniae
- sensitive Staph.
***** gemifloxacin
****** indications
- very poor activity against Pseudomonas aeruginosa
****** spectrum
respiratory pathogens
***** moxifloxacin
****** brand
Avelox
****** indications
- respiratory pathogens, including S. pneumoniae
****** non-indicaations
UTIs
***** ciprofloxacin
****** brand
Cipro
****** spectrum
- enteric Gram(-) rods
- doesn’t cover
  - S. pneumoniae
****** indications
anthrax
****** non-indications
S. pneumoniae
***** norfloxacin
****** brand
Noroxin
****** indication
UTIs only
****** spectrum
Gram(-)
**** warnings
ALL QUINOLONES SHOULD NOT BE CO-ADMINISTERED WITH TPN AND DIVALENT METAL IONS
*** metronidzole
*** nitrofurantoin
** folate synthesis inhibitors
*** dapsone
*** trimethoprim/sulfamethoxazole
** DNA-dependent RNA Polymerase
** RNA inhibitors :l:
*** rifamycins :l:
**** rifampin
**** rifabutin
**** rifapentine
** Protein Biosynthesis :l:
*** tetracyclines :l:
**** tetracycline
**** doxyycline
**** minocycline
**** tigecycline
**** ervacycline
**** omadacycline
*** macrolides :l:
**** erythromycin
**** clarithromycin
**** azithromycin
*** lincosamide :l:
**** clindamycin
*** oxazolidinones :l:
**** linezolid
**** tedizolid
*** amingolycosides :l:
**** plazomicin
**** gentamicin
**** tobramycin
**** amikacin
**** streptomycin
** Tetrahydrofolic Acid
* therapeutics
** bactericidal drugs
- Vancomycin
- Fluoroquinolones
- Penicillin
- Aminoglycosides
- Cephalosporins
- Metronidazole
** bacteriostatic drugs
- Erythromycin
- Clindamycin
- Sulfamethoxazole
- Trimethoprim
- Tetracyclines
- Chloramphenicol
** lower respiratory infections
*** community acquired pneumonia
**** diagnostics :l:
***** chest radiography (CXR)
- most common
- looks for
  - infiltrate
  - patchy consolidation
***** pretreatment blood cultures
test for etiology
***** biomarkers
- C-reactive protein (CRP)
- procalcitonin (PCT)
**** assessment
***** CURB-65
- confusion : 1 point
- BUN ≥20 mg/dL : 1 point
- RR ≥30 bpm : 1 point
- SBP <90 mm Hg or DBP ≤60 mm Hg : 1 point
- age ≥65 : 1 point
**** treatment
***** categories
****** no antibiotic use in the past 3 months and previously healthy
- macrolide
- doxycycline
****** risk factors for drug-resistant /S. pneumoniae/ or comorbidities
- β-lactam + { macrolide, doxycyline }
- respiratory quinolone monotherapy
*** hospital acquired pneumonia
**** goal trough of vancomycin
15-20 mcg/mL
* no coverage against strep pneumon
Cipro
* moxifloxacin
not a drug for UTIs
